Budesonide is an asthma medicine that helps to avoid symptoms. It's a steroid or corticosteroid (cortisone-like medicine). The medicine reduces the intensity of asthma attacks by preventing inflammation in the lungs. Other asthma medications, such as bronchodilators, may be combined with inhaled budesonide to open up restricted breathing airways in the lungs. Budesonide comes in a variety of forms, including powders, suspensions, and tablets. The drug can be breathed by mouth using an inhaler if it is in powder form. It can also be inhaled through the mouth using a customized jet nebulizer (a machine that turns medication into a mist that can be inhaled). Pulmicort, Rhinocort, and Entocort are just a few of the brand names for budesonide.
The budesonide inhaler market is predicted to rise due to an increase in the number of generic budesonide inhaler launches.
The increasing number of generic Budesonide Inhaler Market launches is a major driving force for the budesonide inhaler market's growth. For example, Nephron Pharmaceuticals Corporation (Nephron) introduced generic Budesonide Inhalation Suspension in the United States in 2016. Apotex, Inc. has licensed the Abbreviated New Drug Application (ANDA) to Nephron. AstraZeneca LP manufactures Budesonide Inhalation Suspension, which is the generic equivalent of Pulmicort Respules. Budesonide's manufacturing, marketing, and distribution will be handled by Nephron.
Restraints on the Budesonide Inhaler Market
The side effects of budesonide, such as runny or stuffy nose, sneezing, coughing, sore throat, dry throat, nosebleed, nausea, vomiting, diarrhea, stomach pain, white patches or sores inside the mouth or on the lips, headache, hoarseness, voice changes, or a bad taste in the mouth, are a major restraint on the growth of the budesonide inhaler market. For example, according to the 2017 Product Monograph for Pulmicort Turbuhaler from AstraZeneca Canada Inc., side effects can be seen in 2 to 4% of those taking Pulmicort Turbuhaler (budesonide).
Insights into the Budesonide Inhaler Market by Region
The global budesonide inhaler market is divided into five regions: North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa. Due to increased regulatory approvals of budesonide inhalers, North America is likely to have a leading position in the global budesonide inhaler market. For example, Cipla Ltd. gained final approval from the US Food and Drug Administration (FDA) in November 2017 for its Abbreviated New Drug Application (ANDA) for Budesonide Inhalation Suspension, 0.25mg/2mL, 0.5mg/2mL, and 1mg/2mL to market a generic version of AstraZeneca's Pulmicort Respules. It's used to treat asthma in children aged 12 months to 8 years old, as well as as a preventative measure.
Restraints on the Budesonide Inhaler Market
The side effects of budesonide, such as runny or stuffy nose, sneezing, coughing, sore throat, dry throat, nosebleed, nausea, vomiting, diarrhea, stomach pain, white patches or sores inside the mouth or on the lips, headache, hoarseness, voice changes, or a bad taste in the mouth, are a major restraint on the growth of the budesonide inhaler market. For example, according to the 2017 Product Monograph for Pulmicort Turbuhaler from AstraZeneca Canada Inc., side effects can be seen in 2 to 4% of those taking Pulmicort Turbuhaler (budesonide).
Insights into the Budesonide Inhaler Market by Region
The global budesonide inhaler market is divided into five regions: North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa. Due to increased regulatory approvals of budesonide inhalers, North America is likely to have a leading position in the global budesonide inhaler market. For example, Cipla Ltd. gained final approval from the US Food and Drug Administration (FDA) in November 2017 for its Abbreviated New Drug Application (ANDA) for Budesonide Inhalation Suspension, 0.25mg/2mL, 0.5mg/2mL, and 1mg/2mL to market a generic version of AstraZeneca's Pulmicort Respules. It's used to treat asthma in children aged 12 months to 8 years old, as well as as a preventative measure.
The market for Budesonide Inhalers: A Competitive Analysis
Pfizer Inc., Cipla Limited, Lupin Limited, Cosmo Pharmaceuticals, Takeda Pharmaceutical Company Ltd., Manus Aktteva Biopharma LLP, Abbott Laboratories, Lunan Better Pharmaceutical, Novartis International AG (Sandoz), Mylan N.V., Skyepharma, AstraZeneca Plc., Chiesi Farmaceutici S.p.A, Orion Corporation, Santarus Inc., Synmosa Biopharma Corporation, and Shanghai Sin
Pfizer Inc., Cipla Limited, Lupin Limited, Cosmo Pharmaceuticals, Takeda Pharmaceutical Company Ltd., Manus Aktteva Biopharma LLP, Abbott Laboratories, Lunan Better Pharmaceutical, Novartis International AG (Sandoz), Mylan N.V., Skyepharma, AstraZeneca Plc., Chiesi Farmaceutici S.p.A, Orion Corporation, Santarus Inc., Synmosa Biopharma Corporation, and Shanghai Sin
0 Comments